Similar approach has been described in patients with R/R NHL, where repeat infusion of CD19 CAR‐T‐ cell therapy after pretreatment with ibrutinib led to better in vivo expansion of CAR‐T cells and disease responses [26]. Here, CD19 is linked to non-Hodgkin lymphoma.